project . 2020 - 2025 . On going

Investigating the contribution of gamma-delta T-cells to immunosurveillance of cancer and response to immunotherapy

Wellcome Trust
  • Funder: Wellcome TrustProject code: 220589
  • Funded under: Immune System in Health and Disease Funder Contribution: 698,120 GBP
  • Status: On going
  • Start Date
    01 Sep 2020
    End Date
    31 Aug 2025
Description
Gamma-delta T-cells are critical for protecting against carcinogenesis in mice but clinical associations have been equivocal and human trials of gamma-delta T-cell therapy have been disappointing. Previous studies have been limited by unavailable technologies to describe these cells with sufficient granularity whilst clinical trials have largely focussed on the more numerous V-delta-2 subtype. Using contemporary methods such as TCR-sequencing and ex vivo culture systems to extract gamma-delta T-cells from human tissues, we recently demonstrated that only certain subtypes of these cells, namely the V-delta-1 subtype, are associated with survival in triple-negativ...
Description
Gamma-delta T-cells are critical for protecting against carcinogenesis in mice but clinical associations have been equivocal and human trials of gamma-delta T-cell therapy have been disappointing. Previous studies have been limited by unavailable technologies to describe these cells with sufficient granularity whilst clinical trials have largely focussed on the more numerous V-delta-2 subtype. Using contemporary methods such as TCR-sequencing and ex vivo culture systems to extract gamma-delta T-cells from human tissues, we recently demonstrated that only certain subtypes of these cells, namely the V-delta-1 subtype, are associated with survival in triple-negativ...
Any information missing or wrong?Report an Issue